Clearpoint Neuro Inc (CLPT) - Total Assets
Based on the latest financial reports, Clearpoint Neuro Inc (CLPT) holds total assets worth $93.42 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CLPT net asset quality score to measure how much of total assets are equity-financed.
Clearpoint Neuro Inc - Total Assets Trend (2011–2025)
This chart illustrates how Clearpoint Neuro Inc's total assets have evolved over time, based on quarterly financial data. Check Clearpoint Neuro Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Clearpoint Neuro Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Clearpoint Neuro Inc's total assets of $93.42 Million consist of 65.1% current assets and 34.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 47.0% |
| Accounts Receivable | $7.26 Million | 7.4% |
| Inventory | $8.36 Million | 8.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $13.92 Million | 14.2% |
| Goodwill | $7.47 Million | 7.6% |
Asset Composition Trend (2011–2025)
This chart illustrates how Clearpoint Neuro Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CLPT market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Clearpoint Neuro Inc's current assets represent 65.1% of total assets in 2025, an increase from 50.7% in 2011.
- Cash Position: Cash and equivalents constituted 47.0% of total assets in 2025, up from 4.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 14.2% of total assets.
Clearpoint Neuro Inc Competitors by Total Assets
Key competitors of Clearpoint Neuro Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$91.48 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
LIFETECH SCI.DL-00000125
F:81X
|
Germany | €5.01 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Shanghai Kinetic Medical Co
SHE:300326
|
China | CN¥3.38 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
Clearpoint Neuro Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.79 | 3.53 | 15.62 |
| Quick Ratio | 4.88 | 2.57 | 14.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $45.40 Million | $17.35 Million | $64.12 Million |
Clearpoint Neuro Inc - Advanced Valuation Insights
This section examines the relationship between Clearpoint Neuro Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.31 |
| Latest Market Cap to Assets Ratio | 4.22 |
| Asset Growth Rate (YoY) | 149.4% |
| Total Assets | $97.75 Million |
| Market Capitalization | $412.36 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Clearpoint Neuro Inc's assets at a significant premium (4.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Clearpoint Neuro Inc's assets grew by 149.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Clearpoint Neuro Inc (2011–2025)
The table below shows the annual total assets of Clearpoint Neuro Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $97.75 Million | +149.42% |
| 2024-12-31 | $39.19 Million | -8.14% |
| 2023-12-31 | $42.66 Million | -23.12% |
| 2022-12-31 | $55.49 Million | -15.39% |
| 2021-12-31 | $65.58 Million | +122.17% |
| 2020-12-31 | $29.52 Million | +147.49% |
| 2019-12-31 | $11.93 Million | +51.80% |
| 2018-12-31 | $7.86 Million | -43.47% |
| 2017-12-31 | $13.90 Million | +87.78% |
| 2016-12-31 | $7.40 Million | -26.74% |
| 2015-12-31 | $10.10 Million | -24.53% |
| 2014-12-31 | $13.39 Million | +70.02% |
| 2013-12-31 | $7.87 Million | +41.81% |
| 2012-12-31 | $5.55 Million | +83.20% |
| 2011-12-31 | $3.03 Million | -- |
About Clearpoint Neuro Inc
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which … Read more